Likewise, a study conducted by Blondon et al. demonstrated a significant association of tamoxifen use with decreases in plasma levels of TFPI, which may be an important explanation for the procoagulant risk of tamoxifen in breast cancer patients [45]. The gene discussed is TFPI; the disease is breast carcinoma.